Annual Drug Patent Expirations for MYRBETRIQ
Myrbetriq is a drug marketed by Apgdi and is included in one NDA. It is available from three suppliers. There are eight patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for MYRBETRIQ.
This drug has one hundred and thirty-one patent family members in thirty countries.
The generic ingredient in MYRBETRIQ is mirabegron. Three suppliers are listed for this compound. Additional details are available on the mirabegron profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com